A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
Hematological Malignancies
Interventions
DIAGNOSTIC_TEST

68Ga-Pentixafor and 18F-FDG PET/CT Scan

The imaging agent 68Ga-Pentixafor and 18F-FDG used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is about 4; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.

Trial Locations (1)

710000

RECRUITING

Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER